TY - JOUR
T1 - Long-term effect of additional rehabilitation following botulinum toxin-A on upper limb activity in chronic stroke
T2 - the InTENSE randomised trial
AU - Lannin, Natasha A.
AU - Ada, Louise
AU - English, Coralie
AU - Ratcliffe, Julie
AU - Faux, Steven
AU - Palit, Mithu
AU - Gonzalez, Senen
AU - Olver, John
AU - Schneider, Emma
AU - Crotty, Maria
AU - Cameron, Ian D.
PY - 2022/12
Y1 - 2022/12
N2 - Background: It is common for people with persistent spasticity due to a stroke to receive an injection of botulinum toxin-A in the upper limb, however post-injection intervention varies. Aim: To determine the long-term effect of additional upper limb rehabilitation following botulinum toxin-A in chronic stroke. Method: An analysis of long-term outcomes from national, multicenter, Phase III randomised trial with concealed allocation, blinded measurement and intention-to-treat analysis was carried out. Participants were 140 stroke survivors who were scheduled to receive botulinum toxin-A in any muscle(s) that cross the wrist because of moderate to severe spasticity after a stroke greater than 3 months ago, who had completed formal rehabilitation and had no significant cognitive impairment. Experimental group received botulinum toxin-A plus 3 months of evidence-based movement training while the control group received botulinum toxin-A plus a handout of exercises. Primary outcomes were goal attainment (Goal Attainment Scale) and upper limb activity (Box and Block Test) at 12 months (ie, 9 months beyond the intervention). Secondary outcomes were spasticity, range of motion, strength, pain, burden of care, and health-related quality of life. Results: By 12 months, the experimental group scored the same as the control group on the Goal Attainment Scale (MD 0 T-score, 95% CI -5 to 5) and on the Box and Block Test (MD 0.01 blocks/s, 95% CI -0.01 to 0.03). There were no differences between groups on any secondary outcome. Conclusion: Additional intensive upper limb rehabilitation following botulinum toxin-A in chronic stroke survivors with a disabled upper limb is not more effective in the long-term.
AB - Background: It is common for people with persistent spasticity due to a stroke to receive an injection of botulinum toxin-A in the upper limb, however post-injection intervention varies. Aim: To determine the long-term effect of additional upper limb rehabilitation following botulinum toxin-A in chronic stroke. Method: An analysis of long-term outcomes from national, multicenter, Phase III randomised trial with concealed allocation, blinded measurement and intention-to-treat analysis was carried out. Participants were 140 stroke survivors who were scheduled to receive botulinum toxin-A in any muscle(s) that cross the wrist because of moderate to severe spasticity after a stroke greater than 3 months ago, who had completed formal rehabilitation and had no significant cognitive impairment. Experimental group received botulinum toxin-A plus 3 months of evidence-based movement training while the control group received botulinum toxin-A plus a handout of exercises. Primary outcomes were goal attainment (Goal Attainment Scale) and upper limb activity (Box and Block Test) at 12 months (ie, 9 months beyond the intervention). Secondary outcomes were spasticity, range of motion, strength, pain, burden of care, and health-related quality of life. Results: By 12 months, the experimental group scored the same as the control group on the Goal Attainment Scale (MD 0 T-score, 95% CI -5 to 5) and on the Box and Block Test (MD 0.01 blocks/s, 95% CI -0.01 to 0.03). There were no differences between groups on any secondary outcome. Conclusion: Additional intensive upper limb rehabilitation following botulinum toxin-A in chronic stroke survivors with a disabled upper limb is not more effective in the long-term.
KW - Botulinum toxin type A
KW - Neuroscience
KW - Rehabilitation
KW - Spasticity
KW - Stroke
KW - Wrist
UR - http://www.scopus.com/inward/record.url?scp=85128845064&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1079542
U2 - 10.1186/s12883-022-02672-8
DO - 10.1186/s12883-022-02672-8
M3 - Article
C2 - 35468766
AN - SCOPUS:85128845064
SN - 1471-2377
VL - 22
JO - BMC Neurology
JF - BMC Neurology
IS - 1
M1 - 154
ER -